IL-15 in the Combination Immunotherapy of Cancer

We completed clinical trials of rhIL-15 by bolus, subcutaneous, and continuous intravenous infusions (CIV). IL-15 administered by CIV at 2 mcg/kg/day yielded a 38-fold increase in 10- day number of circulating NK cells, a 358-fold increase in CD56(bright) NK cells and a 5.8-fold increase in CD8 T ce...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Immunol
Autors principals: Waldmann, Thomas A., Dubois, Sigrid, Miljkovic, Milos D., Conlon, Kevin C.
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2020
Matèries:
Immunology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7248178/
https://ncbi.nlm.nih.gov/pubmed/32508818
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.00868
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars